Strides Pharma Science profit and loss

Latest FY26

Revenue: ₹4,859cr+6.4% on FY25
EBITDA: ₹925cr+15.3% on FY25
Net profit: ₹575cr−84.0% on FY25
EPS: ₹60.34−84.5% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	5,213	4,859	4,565	4,051	3,688	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	124	151	58.7	39.7	90.3
	5,337	5,009	4,624	4,091	3,779
	1,848	1,559	1,476	1,341	1,442
	546	362	688	283	188
	−271	38.3	−184	15.9	−2.7
	958	929	863	751	732
	172	179	249	314	261
	217	202	192	221	243
	1,175	1,046	920	916	899
	4,646	4,314	4,204	3,843	3,763
	956	925	803	743	430
	739	723	611	523	187
Profit
	691	695	420	248	16.1
	51.8	−26.8	64.7	−189	−17.0
	743	668	485	58.8	−0.9
	94.9	77.9	46.9	37.3	−31.7
	11.6	16.3	30.6	−5.7	−23.6
	107	94.2	77.5	31.6	−55.3
	1.0	0.5	1.8	−176	−285
	637	575	3,598	−94.3	−212
	636	574	408	27.2	54.4
	0.0	0.0	3,188	54.2	18.6
	97.7	44.0	150	−54.7	7.9
	735	619	3,747	−149	−204
	617	556	3,593	−70.6	−203
	20.2	18.3	4.1	−23.7	−9.7
Per share
	₹66.91	₹60.34	₹390.54	−₹7.76	−₹22.49
	₹66.90	₹60.34	₹390.50	−₹7.77	−₹22.49
Continuing & discontinued operations
	0.0	0.0	3,188	54.2	18.6
Other comprehensive income — detail
	97.7	44.0	150	—	—
	−58.1	−46.7	185	−57.9	−54.2
	−11.0	−9.1	46.1	−2.0	2.6
	—	—	—	−1.9	2.6
	150	61.5	11.8	3.0	64.8
	5.4	−20.1	0.8	—	—
	—	—	—	1.8	0.0
	712	598	3,741	−125	−189
	22.8	20.8	6.8	−24.3	−15.7
Per share — as-filed variants
	₹66.91	₹60.34	₹44.05	−₹13.72	−₹24.56
	₹66.90	₹60.34	₹44.05	−₹13.72	−₹24.56
	₹0.00	₹0.00	₹346.49	₹5.96	₹2.07
	₹0.00	₹0.00	₹346.45	₹5.95	₹2.07
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	3,089	2,900	2,585	2,411	2,062
	59.3%	59.7%	56.6%	59.5%	55.9%
Adjusted (ex-exceptional items) — derived
	691	695	420	248	16.1
	51.8	−26.8	64.7	−189	−17.0
	593	598	3,543	−6.8	−206
	₹62.25	₹62.76	₹384.64	−₹0.56	−₹21.77

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

STAR₹1,097.50

Strides Pharma Science Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersSPARC SUPRIYA SHILPAMED THYROCARE RUBICON VIYASH YATHARTH PARKHOSPSMcap ₹10,116 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Revenue from Operations	3,688.4	4,051.1	4,565.3	4,858.7	5,213.3
Other Income	90.3	39.7	58.7	150.7	124.0
Total Income	3,778.7	4,090.8	4,624.1	5,009.4	5,337.2
Expenses
+ Cost of Materials Consumed	1,441.7	1,341.1	1,475.9	1,558.9	1,848.2
+ Purchases of Stock-in-Trade	187.9	283.4	688.1	361.5	546.2
+ Changes in Inventories	-2.7	15.9	-184.0	38.3	-270.6
+ Employee Benefit Expense	732.0	751.1	862.8	929.0	957.9
+ Finance Costs	261.1	314.4	248.9	178.5	172.1
+ Depreciation & Amortisation	243.3	220.7	192.3	202.4	217.5
+ Other Expenses	899.3	916.2	919.8	1,045.7	1,175.2
Total Expenses	3,762.6	3,843.0	4,203.6	4,314.3	4,646.5
EBITDA	430.2	743.3	802.8	925.3	956.3
EBIT	186.9	522.6	610.6	722.9	738.9
Profit
PBT before Exceptional Items	16.1	247.8	420.4	695.1	690.8
+ Exceptional Items	-17.0	-189.0	64.7	-26.8	51.8
Pretax Income	-0.9	58.8	485.1	668.2	742.5
+ Current Tax	-31.7	37.3	46.9	77.9	94.9
+ Deferred Tax	-23.6	-5.7	30.6	16.3	11.6
Tax Expense	-55.3	31.6	77.5	94.2	106.6
+ Share of Associates & JVs	-285.3	-175.7	1.8	0.5	1.0
Net Income	-212.3	-94.3	3,597.5	574.5	637.0
+ Net Income — Continuing Ops	54.4	27.2	407.6	574.1	636.0
+ Net Income — Discontinued Ops	18.6	54.2	3,188.1	0.0	0.0
+ Other Comprehensive Income	7.9	-54.7	149.8	44.0	97.7
Total Comprehensive Income	-204.4	-149.0	3,747.3	618.5	734.7
Net Income to Common	-202.6	-70.6	3,593.5	556.2	616.8
Minority Interest	-9.7	-23.7	4.1	18.3	20.2
Per Share
Basic EPS	-22.49	-7.76	390.54	60.34	66.91
Diluted EPS	-22.49	-7.77	390.50	60.34	66.90
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax	18.6	54.2	3,188.1	0.0	0.0
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	149.8	44.0	97.7
+ Items NOT to be Reclassified to P&L	-54.2	-57.9	185.0	-46.7	-58.1
+ Tax on Items NOT to be Reclassified	2.6	-2.0	46.1	-9.1	-11.0
+ Tax on Items NOT to be Reclassified — alt tag	2.6	-1.9	—	—	—
+ Items to be Reclassified to P&L	64.8	3.0	11.8	61.5	150.1
+ Tax on Items to be Reclassified	—	—	0.8	-20.1	5.4
+ Tax on Items to be Reclassified — alt tag	0.0	1.8	—	—	—
Comprehensive Income — Owners of Parent	-188.7	-124.7	3,740.5	597.7	711.9
Comprehensive Income — Non-controlling Interests	-15.7	-24.3	6.8	20.8	22.8
Per Share — as-filed variants
Basic EPS — Continuing Operations	-24.56	-13.72	44.05	60.34	66.91
Diluted EPS — Continuing Operations	-24.56	-13.72	44.05	60.34	66.90
Basic EPS — Discontinued Operations	2.07	5.96	346.49	0.00	0.00
Diluted EPS — Discontinued Operations	2.07	5.95	346.45	0.00	0.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	2,061.5	2,410.6	2,585.4	2,900.0	3,089.5
Gross Margin %	55.89	59.50	56.63	59.69	59.26
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	16.1	247.8	420.4	695.1	690.8
− Exceptional Items (reconciliation)	-17.0	-189.0	64.7	-26.8	51.8
Net Income Adj (tax-effected)	-205.5	-6.8	3,543.2	597.6	592.7
EPS Adj	-21.77	-0.56	384.64	62.76	62.25
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	90.3	91.9	92.2	92.2	92.2

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.